ADAM RHOADES: Open Payments
NPI 1659519692 · MACON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$704 in 34 payments from 14 companies in 2025. Trend: 2023 $1,008 · 2024 $1,258 · 2025 $704
Food & beverage: $701Education: $3
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $146 |
| Novartis Pharmaceuticals Corporation | 5 | $102 |
| Amgen Inc. | 4 | $88 |
| Novo Nordisk Inc | 4 | $77 |
| Travere Therapeutics, Inc. | 5 | $65 |
| Daiichi Sankyo Inc. | 2 | $50 |
| ABBVIE INC. | 2 | $41 |
| Aurinia Pharma U.S., Inc. | 1 | $27 |
| Vifor Pharma, Inc. | 1 | $24 |
| Abbott Laboratories | 1 | $19 |
Products named: JYNARQUE, Fabhalta, KRYSTEXXA, Wegovy, INJECTAFER, UBRELVY, REXULTI, LUPKYNIS.
Industry payments across GA — which companies pay providers there.
